Vanguard Investments Australia
TSHA icon

Vanguard Investments Australia’s Taysha Gene Therapies TSHA Stock Holding History

Vanguard Investments Australia’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$244K Hold
35,887
– – ﹤0.01% 2024
2026
Q1 		$160K Buy
+35,887
New +$167K ﹤0.01% 2135

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Vanguard Investments Australia's TSHA Position: Q2 2026 in Review

Vanguard Investments Australia held its Taysha Gene Therapies (TSHA) position steady in Q2 2026 at 35,887 shares worth $244K. The position accounts for ﹤0.01% of the portfolio, ranked #2024.

Vanguard Investments Australia first reported a position in TSHA in Q1 2026 and has held it in 2 quarters since. 192 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Vanguard Investments Australia held 35,887 shares of Taysha Gene Therapies worth $244K as of Q2 2026.
  • Vanguard Investments Australia left its Taysha Gene Therapies share count unchanged in Q2 2026.
  • Taysha Gene Therapies made up ﹤0.01% of Vanguard Investments Australia's portfolio in Q2 2026, its #2024 holding.
  • Vanguard Investments Australia first reported a position in Taysha Gene Therapies in Q1 2026 and has held it in 2 quarters since.
  • 192 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.